These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16238905)

  • 21. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
    Endicott J; McLaughlin TP; Grudzinski AN
    J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
    Yunusa I; Gagne JJ; Yoshida K; Bykov K
    JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
    Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
    Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
    Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
    J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
    Assimon MM; Brookhart MA; Flythe JE
    J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
    Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
    J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective serotonin reuptake inhibitor exposure.
    Fitzgerald KT; Bronstein AC
    Top Companion Anim Med; 2013 Feb; 28(1):13-7. PubMed ID: 23796482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
    Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E
    Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.
    Dunham KE; Venton BJ
    J Neurochem; 2022 Sep; 162(5):404-416. PubMed ID: 35736504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant therapy with anxiolytics or hypnotics and maintenance of initial SSRI therapy.
    Shields SA; Gregor KJ; Young CH; James SP
    Pharmacotherapy; 1998; 18(6):1298-303. PubMed ID: 9855330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
    Lam D; Gorman DA; Patten S; Pringsheim T
    Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot.
    Yazdy MM; Mitchell AA; Louik C; Werler MM
    Epidemiology; 2014 Nov; 25(6):859-65. PubMed ID: 25171134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism.
    Isa Kara M; Ertaş ET; Ozen E; Atıcı M; Aksoy S; Erdogan MS; Kelebek S
    Arch Oral Biol; 2017 Aug; 80():69-74. PubMed ID: 28391088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
    Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
    J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
    Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.